Similar articles

• Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.

  Leebeek FW, Boersma E, Cannon CP, van de Werf FJ, Simoons ML. Leebeek FW, et al. Eur Heart J. 2002 Mar;23(6):444-57. doi: 10.1053/euhj.2001.2751. Eur Heart J. 2002. PMID: 11863347 Review. No abstract available.
• Use of GPIIb/IIIa inhibitors in cardiovascular medicine.

  Ahrens I, Peter K, Bode C. Ahrens I, et al. Expert Rev Cardiovasc Ther. 2003 Jul;1(2):233-42. doi: 10.1586/14779072.1.2.233. Expert Rev Cardiovasc Ther. 2003. PMID: 15030283 Review.
• Platelet glycoprotein IIb/IIIa receptor inhibitors: is their future as bright as their past?

  Leesar MA. Leesar MA. Catheter Cardiovasc Interv. 2008 Jun 1;71(7):907-8. doi: 10.1002/ccd.21622. Catheter Cardiovasc Interv. 2008. PMID: 18498141 No abstract available.
• The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.

  Bolognese L. Bolognese L. Curr Med Res Opin. 2007 Jun;23(6):1217-26. doi: 10.1185/030079907X188143. Epub 2007 Apr 23. Curr Med Res Opin. 2007. PMID: 17559721 Review.
• [Reflections on GPIIb/IIIA inhibitors ... and all around ...].

  Neri Serneri GG. Neri Serneri GG. G Ital Cardiol. 1999 Apr;29(4):467-71. G Ital Cardiol. 1999. PMID: 10327329 Review. Italian. No abstract available.